Colorectal Cancer

  1. RAS Mutation Test
    1. Indication: metastatic colorectal cancer
    2. Function: predict the effectivity of anti epidermal growth factor receptor/ EGFR (cetuximab, panitumumab)
    3. Sample: histopathology (resection or biopsy) fixed by neutral buffer formalin 10% in cell block or stained/ unstained coated slide with more than 200 tumor cells and contained more than 50% tumor cells, primary or metastatic site and before or after chemotherapy are eligible
    4. Analyte: DNA (KRAS Exon 2 Codon 12 and 13, Exon 3, Exon 4; NRAS Exon 2, 3, 4)
    5. Method: real time PCR
    6. Interpretation: wild type is eligible for anti EGFR therapy
    7. TAT: 7 working days
    8. Guideline: NCCN 3.2015 and ESMO
    9. External quality assurance: ISO 15189-2007ESP 2012

  2. BRAF Mutation Test
    1. Indication: colorectal cancer
    2. Function: asses prognosis value of metastatic colorectal cancer or classify sporadic or hereditary non polyposis colorectal cancer
    3. Sample: histopathology (resection or biopsy) fixed by neutral buffer formalin 10% in cell block or stained/ unstained coated slide with more than 200 tumor cells and contained more than 50% tumor cells
    4. Analyte: DNA
    5. Method: real time PCR
    6. Interpretation: wild type is good prognosis or possibly hereditary non polyposis colorectal cancer
    7. TAT: 7 working days
    8. Guideline: NCCN 3.2015NCCN 1.2015 and ESMO

  3. MLH1 MSH2 Expression Test (MSI IHC)
    1. Indication: colorectal cancer
    2. Function: asses prognosis value of early stage colorectal cancer or asses risk of hereditary non polyposis colorectal cancer
    3. Sample: histopathology (resection or biopsy) fixed by neutral buffer formalin 10% in cell block or unstained coated slide with proportion between tumor cell and normal cell are 50:50
    4. Analyte: protein
    5. Method: immunohistochemistry
    6. Interpretation: no expression in tumor cell (MSI +) is good prognosis or possibly hereditary non polyposis colorectal cancer
    7. TAT: 7 working days
    8. Guideline: NCCN 1.2015
Advertisements